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ABSTRACT 
Tartrate- resistant acid phosphatase (TRAP) exists in two isoforms, TRAP 5a which is 
monomeric and TRAP 5b which is a dimer generated by proteolytic cleavage of TRAP 5a, that 
exhibit different functions and localizations. TRAP 5a is expressed by adipose tissue 
macrophages and secreted into the extracellular environment and has been shown to lead to 
hyperplastic insulin- sensitive obesity when over-expressed in mice. In bone, TRAP is 
suggested to interact with the heparan sulfate proteoglycan (HSPG) glypican-4. In humans, 
TRAP 5a serum levels and TRAP in adipose tissue correlate to BMI. TRAP 5a has been shown 
to have a stimulatory effect on the proliferation and differentiation of pre-adipocytes, pre-
osteoblasts and hematopoietic cells but the mechanism of action remains unknown. The aims 
of this thesis were (1) to develop an ELISA for quantification of human TRAP 5a and to 
evaluate TRAP 5a levels in lean vs. obese individuals and (2) to investigate the mechanism of 
action of TRAP 5a in pre-adipocytes and the effects on the homeostasis-related events such as 
cell cycle entry, differentiation and migration using the pre-adipocyte cell line 3T3-L1. A 
TRAP 5a ELISA was developed by generation of monoclonal antibodies specific for TRAP 5a 
and used to measure TRAP 5a in serum from lean and obese females. TRAP 5a in serum of 
obese females was reduced compared to lean but a positive correlation between BMI >30 and 
serum levels of TRAP 5a was identified. Regarding effect of TRAP 5a on 3T3-L1 cells, TRAP 
5a was shown to bind to the components of extracellular matrix (ECM) heparan sulfate and 
nidogen-2. TRAP 5a was shown to bind to the pre-adipocyte cell membrane and to co-localize 
with HSPG glypican-4. After cell surface binding, TRAP 5a is endocytosed in a caveolae-
mediated manner and co-localizes with early endosomal marker Rab-7. TRAP 5a was also 
observed in multivesicular bodies but did not co-localize with lysosomal marker LAMP-1. 
Mesenchymal stem cells, fibroblasts and pre-osteoblasts were also tested for their ability to 
bind TRAP 5a and only pre-osteoblasts exhibited TRAP 5a endocytosis. TRAP 5a was shown 
to enhance the number of cells entering S phase after cell cycle arrest by serum deprivation and 
to increase cyclin D1 levels. In a phosphorylation signaling array for proteins of the Akt 
pathway it was shown that TRAP 5a causes increased inactivation phosphorylation of GSK3β 
that is most likely not dependent on Akt since Akt activation phosphorylation was reduced after 
TRAP 5a treatment. Proteins controlling cell cycle arrest and apoptosis p53, p38 and Bad 
exhibited altered phosphorylation pattern after TRAP 5a treatment that could potentially lead 
to their inactivation. TRAP 5a treatment induced changes in morphology of pre-adipocytes and 
enhanced their migration. Focal adhesion protein (FAK), paxillin and actin were down- 
regulated after TRAP treatment indicating cytoskeletal changes and changes in the adhesion 
pattern. TRAP 5a treatment lead to enhanced lipid droplet acquisition after 2 days of 
differentiation induction in pre-adipocytes. In summary, TRAP 5a interacts with components 
of the ECM, binds to the surface of pre-adipocytes and co-localizes with glypican-4 and is 
endocytosed in a caveolae -dependent manner. Treatment of pre-adipocytes with TRAP 5a 
leads to enhanced cell numbers, increased migration, morphological changes and increased 
differentiation, all consistent with a growth factor-like role for TRAP 5a in adipose tissue. 
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1 INTRODUCTION 
1.1 TISSUE HOMEOSTASIS 
Tissue homeostasis refers to the maintenance of tissue in a functional state and is regulated by 
a variety of biological events regulating the life span of cells such as cell proliferation i.e. cell 
division, differentiation i.e. cell maturation, migration i.e. cell movement and cell death.  
Tissues are multicellular structures comprised of different cell types. Tissue- specific cells are 
differentiated cells that have a particular function that can vary depending on the type of tissue 
e.g. a metabolic function like e.g. hepatocytes in liver or storage function (adipocytes in adipose 
tissue) or structural/barrier function such as keratinocytes in skin. Apart from differentiated 
cells, tissues contain progenitor/precursor cells, committed to a certain cell lineage, but not 
fully differentiated and retaining the ability, although reduced compared to e.g. stem cells, to 
proliferate (e.g. pre-adipocytes in adipose tissue). A fraction of stem cells named adult stem 
cells reside in tissue and serve as a reservoir pool for tissue regeneration of dying cells and 
maintain homeostasis in case of damage. Immune cells are additionally an important part of a 
tissue. Apart from dendritic cells and mast cells, resident macrophages are present in the stroma 
and are responsible for clearing of cells undergoing apoptosis and mediating the inflammatory 
response during tissue damage.  
1.1.1 How is cell communication mediated? 
Tissue homeostasis and the events described above (cell number regulation, cell migration and 
differentiation) are dependent on soluble signals from the extracellular environment (ECM), 
interaction of the cells with the ECM as well as with other cells. 
 ECM is involved in tissue homeostasis and cellular events in various ways. Growth factors 
can bind to the ECM and remain there until ECM degradation leads to their release and binding 
to the cells. Growth factors bind by the use of heparan sulfate (HS) of the ECM e.g. epidermal 
growth factor (EGF) and hepatocyte growth factor (HGF) and on heparan sulfate proteoglycans 
(HSPGs). Degradation of the ECM can lead to release of these factors once they are needed. 
Other growth factors, e.g. fibroblast growth factor  (FGF) and transforming growth factor 
(TGF) use the proteoglycans (PG) of the ECM for binding to the cells, thus ECM facilitates the 
binding 1. In other cases, the binding of growth factors to ECM serves a different purpose that 
is to make the growth factors available to the cells. Moreover, proteins of the ECM such as 
laminin contain intrinsic sequences (e.g. EGF-like domains) and have been suggested to 
directly bind to cell receptors and induce cell signalling 1.  
Mesenchymal stem cell (MSC) commitment to a certain cell lineage is also dependent on 
factors of the ECM that will provide the appropriate signals for the cells to differentiate. 
Formation of adipocyte precursors (pre-adipocytes) is impaired by the presence of the ECM 
component fibronectin and the binding to its receptor integrin α5/β1 2. This binding causes the 
levels of the Rho GTPase RAC to remain high, thus inhibiting adipocyte differentiation. Rho 
GTPases are important regulators of MSC commitment as they influence the shape of the cells 
and for e.g. adipocytes, changes in shape are crucial for differentiation 2. The extracellular 
environment can also be altered by the activation of matrix metalloproteinases (MMPs) and 
tissue inhibitors of MMPs (TIMPs) and influence cell lineage commitment, e.g. MMP14 and 
TIMP3 are involved in adipocyte lineage commitment 2.  
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1.1.2 Major endocytosis route for growth factors 
Once bound to their receptors, growth factors can follow various routes to complete the 
downstream signalling. Endocytosis can lead to different outcomes, such as signal reduction 
by receptor degradation, downstream signalling by interaction with proteins of the endocytic 
vesicles or signalling enhancement by receptor recycling.   
The main mechanism of growth factor endocytosis are the clathrin- dependent and clathrin -
independent endocytosis (Figure 1). One of the most common mechanisms of clathrin- 
dependent endocytosis is via β-arrestins that bind to activated (phosphorylated due to ligand 
binding) receptors, e.g. G-protein coupled receptors (GPCRs) and clathrin and adaptor protein 
2 (AP2) thus forming an endocytic complex 3.  
The most common clathrin- independent endocytosis pathways is mediated via caveolae. 
Caveolin-1 interaction with cholesterol and phosphorylation of caveolin-1 are two of the 
mechanisms that are required for the formation of caveolae 4,5. Both clathrin- and caveolae- 
mediated endocytosis require the presence of dynamin for the formation of clathrin- and 
caveolae-coated pits and for later invagination of vesicles by hydrolyzing guanosine-5'-
triphosphate (GTP) 6,7. Downstream endocytosis can follow different routes. The first step for 
both clathrin- and caveolae- mediated endocytosis is the formation of early endosomes, where 
signalling transduction can take place via components Rab5 together with early endosomal 
antigen (EEA) (canonical endosome signalling) or APPL by formation of complex with Protein 
kinase B (PKB) also known as Akt and Glycogen synthase kinase 3 (GSK3β) leading to its 
phosphorylation and downstream signalling 8. After early endosomes, receptor signalling can 
follow alternative routes. Receptor can be transported back to the cell membrane via recycling 
endosomes that contain Rab-4 or Rab-11. Duration of signalling can be determined by the 
action of recycling endosomes 8. Apart from recycling, receptors can be translocated to late 
endosomes and multivesicular endosomes/bodies for further transfer to the lysosomes for 
degradation but also for further signal enhancement.  Late endosomes are characterized by the 
presence of Rab-7 that replaces the early endosome component Rab-5 9.  
For many growth factors, endocytosis takes place in order to sustain the signal by receptor 
recycling or in other cases to remove the ligand from the cell surface and transfer it to the 
lysosomes for degradation and signal reduction/deactivation. The endocytosis route can also 
be dependent on the ligand concentration. For example, EGF can use clathrin- dependent 
endocytosis for signal transduction at low concentrations but caveolae-dependent endocytosis 
for signal down-regulation at high concentrations 10. For other types of signalling, e.g. 
wingless/integration-1 (wnt) signalling, endocytosis via clathrin can lead to signal down-
regulation, while clathrin-independent endocytosis to sustainment of signalling 11.  
Endocytosis can serve other purposes such as transmitting the signal from the cell membrane 
to specialized compartments where signalling is required. This is of particular importance in 
processes such as motility and migration of cells, where it has been shown that clathrin- and 
Rab5-mediated endocytosis is responsible for localized signalling of Rac that leads to actin re-
organization and cell migration 12. Finally, endocytosis alone can be determining for signal 
transduction, e.g. TGF-β binds to its receptor thus leading to its activation by phosphorylation 
and formation of endosomes, it causes the recruitment of SMAD2 by SMAD Anchor for 
Receptor Activation (SARA). This enables the phosphorylation of SMAD2 by TGFβ receptor 
(TGFβR) and its translocation to the nucleus for initiation of transcription 13,14. Multivesicular 
bodies (MVB) are actively participating in and are vital for signalling. GSK3β signalling via 
Wnt is dependent upon endocytosis and MVB formation 15.  
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1.1.2.1  Growth factor secretion from cells that regulate signals 
Upon translation most growth factors and proteins follow conventional secretory pathways 
mediated via endoplasmic reticulum (ER)/golgi. Newly synthesized proteins can be transferred 
to ER and exit in coat-protein II (COP-II) vesicles to enter golgi and exit in coat-protein I (COP-
I) coated vesicles that in their turn use SNAP Receptor (SNARE) complexes and a series of 
fusion of vesicles to exit through the cell membrane 16. In the absence of internal signalling 
peptides that will guide them to the ER, proteins can follow alternative secretory pathways 17 
that can bypass the golgi and be transmitted directly to the cell membrane or be mediated via 
caspase-1 17. Non-conventional secretory pathways can be determining for the protein’s 
biochemical properties, e.g. FGF-2 follows ER/Golgi-independent secretion and when secreted 
via ER/golgi loses its ability to bind to HSPGs 18.  
1.1.3 Cell number regulation 
Tissue cell number is a balance between cell proliferation and cell death. In tissue, stem- and 
precursor cells reside without proliferating until a demand for new cells arises. Hence, these 
cells undergo transition from G1 to S phase by surpassing the restriction points in G1. This 
transition is regulated by a ‘gas and break’ system of signalling.  The ‘gas’ will lead the cells 
to proliferation, while the ‘break’ will trigger (1) cell cycle arrest where cells will remain in G1 
phase (also called G0) until further stimulation, (2) senescence where the cells will lose their 
ability to enter the cell cycle but will remain metabolically active or (3) cell death.   
The gas in the transition of cells from G1 to S phase is the presence of mitogens which stimulate 
expression/activation of proteins needed for entering S phase by surpassing the G1/S restriction 
point. Mitogens such as EGF, insulin-like growth factor (IGF) and platelet-derived growth 
Figure 1. Endocytosis routes. Endocytic vesicles containing clathrin or caveolin and lipid rafts. After 
endocytosis there is formation of early endosomes that lead to recycling endosomes and transfer again to the 
membrane or to multivesicular bodies and late endosomes leading to lysosomal degradation. 
 4 
factor (PDGF) are responsible for the primary signal. Mitogens bind to receptor tyrosine 
kinases (RTKs) causing their dimerization. 1920.  Activation of RTKs  leads to phosphorylation 
and activation of Phosphoinositide 3-kinase (PIK3) that transiently activates Akt, thus causing 
inactivation of GSK3β by phosphorylation 20. GSK3β when active phosphorylates β-catenin 
that will lead to its degradation before translocation to the nucleus, activation of E2F and 
initiation of transcription 21 (Figure 2). Additionally,  GSK3β can regulate degradation of cyclin 
D122,23 that is vital for the transition from G1 to S phase 24. Apart from Akt 25, GSK3β activity 
and β-catenin accumulation can also be regulated by the Wnt signalling pathway 
26.Additionally after surpassing the restriction point controlled by Rb, transition from G1 to S 
phase requires the anchorage of cells which constitutes  a second restriction point that is 
controlled independently of Rb 27. 
Cell number is not only regulated by mitogens but also by cell cycle arrest, senescence and 
apoptosis signals that make up the ‘break’ in cell cycle progression. In the absence of mitogenic 
stimuli (e.g. in vitro during serum deprivation), cells will remain at the phase before the G1 
restriction point (cell cycle arrest/G0)  but will retain the ability to start proliferation and this 
phase is characterized by low levels of cyclins 28. However, cells can also go into 
hypermitogenic cell cycle arrest that, unlike G0, is characterized by high levels of cyclins and 
cyclin dependent kinases (CDKs) and activated mitogenic pathways but also the activation of 
CDK inhibitors such as p21 and p16 28. Due to the activation of CDK inhibitors, evasion of 
hypermitogenic cell cycle arrest can occur not by the presence of mitogens but instead by 
activation of downstream targets such as E2F 28. When ability for cell cycle progress is lost due 
to telomere shortage or by the presence of stress factor e.g. reactive oxygen species (ROS) or 
non-physiological conditions  cells can undergo irreversible cell cycle arrest named senescence 
28. The response and molecular mechanisms controlling senescence vary depending on the 
stimuli 29, but in most cases, cell senescence involves p53 activation which in turn leads to the 
activation of CDK inhibitors p16, p21 and p15 29,30 that inhibit the phosphorylation of pRb thus 
leaving it active and able to supress E2F 31. Interestingly, unlike cells in cycle arrest, senescent 
cells remain metabolically active 29. Cell cycle progress is dependent on inactivation or down-
regulation of apoptotic signals from anti-oncogenic proteins. For instance p53, p38, c-myc and 
JNK need to be down-regulated for cell cycle progress 32,33, however c-myc has been shown to 
promote apoptosis or proliferation depending on the concentration of mitogens and its activity 
has been shown to be regulated also via the Wnt signalling pathway 34. Apart from surpassing 
the restriction points, completion of cell cycle includes an increase in cell mass (cell growth).  
Mechanistic target of rapamycin (mTOR) is one of the main regulators of cell growth 
stimulation and its activity has also been associated with phosphorylation by Akt 20.  
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1.1.4 Cell recruitment and migration 
When there is need for tissue regeneration and /or tissue repair, recruitment of monocytes and 
stem cells from the blood stream to the tissue site is necessary. New cells need to migrate and 
infiltrate the tissue site where they proliferate and mature to differentiated cells in order to form 
new functional tissue. For recruitment, circulating cells in the blood need to be exposed and 
react to chemokines, adhere to and cross the endothelial barrier and finally move to the site 
where tissue needs to be repopulated.  
Cells can be recruited in the presence or absence of an inflammatory signal.  In the absence of 
inflammatory signals migration can be mediated via CXCL14 35. Inflammation -induced 
migration of monocytes is regulated via Chemokine (C-C motif) ligands (CCL) CCL2, CCL3 
and Chemokine (C-X-C motif) ligand CX3CL1 35. Additional chemokines (e.g. CCL9) are 
responsible for their further recruitment to the lymph nodes. When chemokines bind to their 
receptors in the cells, they activate Ras-proximate-1 (RAP1) via cyclic adenosine 
monophosphate (cAMP) and exchange protein directly activated by cAMP (EPAC) which in 
turn binds to RALP. The RALP and RAP1 complex is associated to integrins and together with 
talin they induce morphological changes in the tails of α and β subunits of integrins giving them 
the ability to bind to intracellular adhesion molecular 1 (ICAM1) and vascular cell-adhesion 
molecule 1 (VCAM1) that are present on the surface of endothelial cells, thus inducing stronger 
adhesion. Integrins do not have activity potential on their own so they associate with other 
proteins and form complexes 36. The C-terminal tails of integrins associate with focal adhesion 
Figure 2. Cell cycle progression. Mitogens bind to RTKs leading to their activation. Downstream signalling 
activating PIK3 and Akt leads to de-activation of GSK3β and β-catenin translocation to the nucleus and 
transcription initiation. In the presence of high concentrations of mitogens, cells go into cell cycle arrest by 
expression of cdk inhibitors. Absence of mitogens leads to cell cycle arrest (G0). In the presence of stress or 
other stimuli cells lose their ability to enter the cell cycle and go into senescence controlled by p21, p16, p15 
and p53. R= restriction point 
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kinase (FAK) and paxillin which cause the complex in a phosphorylation-dependent manner 
to bind to vinculin and actin via talin.   This complex leads to actin reorganization with 
migration and adhesion effects 36,37. Moreover, activation of integrins leads to Rho GTPases 
activation that has an effect in actin re-organization. Integrin also causes up-regulation of lipid 
kinase activity and subsequent increase of Phosphatidylinositol 4,5-bisphosphate (PIP2) that 
lead to downstream signalling of Akt, Erk and c-Jun N-terminal kinase (JNK) and thus cause 
effects on proliferation, survival and differentiation. Additionally, increase in PIP3 leads to 
cytoskeletal re-organization and changes in cell polarity.  
Stem cells are also recruited to the tissue when there is a need for tissue repair or regeneration. 
Stem cell recruitment and migration is also mediated via chemokine, chemokine receptor and 
integrin activation as described above. Chemokine Stromal cell-derived factor 1 (SDF-1) and 
its receptor CXCR4 are the main mediators of stem cell migration, and SDF-1 is expressed in 
bone marrow leading to stem cells remaining there. When there is a need for stem cell 
recruitment to tissue, this tissue releases SDF-1 leading to recruitment of stem cells to the site 
where they are needed by the same downstream pathway as described for monocytes 38.  
1.1.5 Cell differentiation 
Once precursor/progenitor cells have reached the site where tissue repair or tissue regeneration 
is required, exposure to the microenvironment leads to their cell differentiation. Factors in the 
microenvironment, growth factors and their respective receptors can have a determining effect 
on the lineage commitment of cells and their subsequent differentiation. Mesenchymal stem 
cell commitment to a specific lineage e.g. bone or adipose is regulated by various signalling 
proteins such as wnts 39, bone morphogenetic proteins (BMPs) 40, but also by constituents that 
comprise the extracellular matrix (ECM)41. Wnt signalling occurs via pathways known as the 
canonical pathway and an alternative pathway named non-canonical pathway (Figure 3). Wnts 
in the canonical pathway (Wnt10b) act by binding to low-density lipoprotein receptor-related 
protein (LRP) co-receptors and frizzled receptor leading to structural changes in frizzled 
causing the binding and activation of Dishevelled and inhibition of GSK3β activity 42.  
Canonical wnt signalling affects mesenchymal stem cells in various ways,  resulting in 
inhibition or promotion of osteogenesis and adipogenesis depending on the level of 
maturation/differentiation of the mesenchymal stem cells 39.  
Mesenchymal stem cells in early stages of their lineage differentiation remain proliferative and 
undifferentiated when canonical wnt signalling is active. In MSC committed to osteoblast 
lineage cells (pre-osteoblasts) but not mature cells, wnt10, wnt3a and wnt1 can promote 
differentiation by activating the transcription of Runx2 11. In committed  adipocyte lineage cells 
(pre-adipocytes), canonical wnt signalling mainly by ligand wnt10b can inhibit differentiation 
by blocking CCAAT/enhancer binding protein α (C/EBPα) and PPARγ and the downstream 
protein adipocyte protein 2 (aP2)43.  
Non-canonical wnt pathways act independently of the frizzled receptor and can also mediate 
β-catenin accumulation or act independently of β-catenin (Figure 3). Wnt5a binding to other 
receptors than frizzled, also inhibits adipogenesis, by activating SETB1 that forms complex 
with chromodomain-helicase-DNA-binding protein 7 (CHD7) and nemo-like kinase NLK 
preventing peroxisome proliferator-activated receptor α (PPARγ) from transcribing adipocyte 
differentiation- related genes. wnt5b on the other hand, by binding to receptors other than 
frizzled, prevents β-catenin from translocating to the nucleus thus promoting adipocyte 
differentiation43.  
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1.2 ADIPOSE TISSUE HOMEOSTASIS 
1.2.1 Adipose tissue as an endocrine and metabolic organ  
Adipose tissue is a metabolic organ responsible for energy uptake, storage of triglycerides (TG) 
and release of free fatty acids (FFA) 44, for hormone production and secretion and for secretion 
of adipokines that contribute to cross-talk with other organs and regulation of intermediary 
metabolism 45. Hormones secreted from adipose tissue  e.g. leptin have been shown to affect 
metabolism, whole body homeostasis and energy regulation 46–48.  
1.2.1.1 Cell types in adipose tissue 
Adipose tissue compromises mainly of adipocytes, the differentiated tissue specific cells that 
store fat. Adipocytes are characterized by the presence of one or several lipid droplet(s) that 
occupy the majority of the cell cytoplasm and which are  controlled in size by the presence of 
perilipin 49. Adipose tissue additionally contains adipocyte precursors (mesenchymal stem cells 
and pre-adipocytes) that reside in the tissue until tissue regeneration is needed, when they 
mature to fully differentiated adipocytes and resident macrophages that are involved in tissue 
homeostasis.  
 
 
Figure 3. Wnt signalling pathways. A) Canonical Wnt signalling pathway. Wnt 10b binds to frizzled 
and LRP 5/6 leading to complex formation with dishevelled, inhibition of GSK3β and translocation of 
β-catenin to the nucleus. B) Non-canonical Wnt pathway, Wnt 5b binds to receptors that lead to 
inhibition of translocation of β-catenin to the nucleus and inhibition of TCF transcription. C) Non-
canonical β-catenin independent pathway. Wnt 5a binds to receptors leading to complex formation of 
CHD7, SETDB1 and NLK and transcription of PPARγ 
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1.2.1.2 Main components of the ECM in adipose tissue  
The ECM composition of adipose tissue plays an important role in adipocyte maturation and 
is necessary for the change in the cell-cell contact and change of the cell morphology during 
adipocyte differentiation 44. During adipocyte differentiation,  changes in the composition of 
ECM  have been observed such as increases in collagen IV, laminin and nidogens 50–53 
1.2.1.3 Cell number  
Formation of adipose tissue occurs from mesoderm 54 during early stages of  development. 
Interestingly, even though the number of adipocytes remains stable during adulthood there is a 
10% annual turnover 55,56 of adipocytes, resulting to a need for adipocyte development from 
pre-adipocytes and mesenchymal stem cells. There are various different factors contributing to 
adipose tissue homeostasis and turnover, among which resident macrophages 57 and ECM 
components 44 appears to be of particular importance.  
 
1.2.2 Mesenchymal stem cells 
Adipocytes, the main cell type in adipose tissue are derived from mesenchymal stem cells. 
MSCs were first described by Friedstein et al. in 1966 58 and are non-hematopoietic stem cells 
that have the ability to differentiate into various types of tissue such as muscle, cartilage, bone 
and adipose tissue (Figure 4) 59,60 .  
 
 
Figure 4. Mesenchymal stem cell lineage.   Mesenchymal stem cell differentiation can lead to several different 
types of tissue. Trans-differentiation (TD) potential has been observed between adipocytes and osteoblasts and 
between chondrocytes and osteoblasts indicating a close relationship between those pre-cursors 
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Among the cell types that MSCs can differentiate to, pre-osteoblasts and pre-adipocytes are  
very close phenotypically and depend on the same signalling pathways that could inhibit 
differentiation towards one lineage and activate the other 39,61,62. Wnt signalling, BMPs and 
PPARγ can guide the signalling towards adipogenesis or osteogenesis from MSCs, where e.g.  
wnt10b and wnt 5a lead the cells towards osteogenesis while wnt 5b leads the cells towards 
adipogenesis 2 and it has also been shown that differentiated cells can transdifferentiate from 
one cell type to the other, e.g. osteoblast can trans-differentiate to adipocytes 63,64 but also 
chondrocytes can trans-differentiate to osteoblasts 65,66. 
 
1.2.3 From pre-adipocytes to adipocytes 
Adipocyte differentiation has been studied extensively in vitro by the use of the murine 
fibroblast-like cell line 3T3-L1. In 1974, Meuth and Green described the ability of 3T3-L1 cells 
who have a fibroblast-like morphology to acquire lipid droplets and mature to adipocytes after 
stimulation with a hormone cocktail 67 and since then 3T3-L1 have been used as a model for 
both cell cycle and differentiation studies of pre-adipocytes to adipocytes. Pre-adipocyte to 
mature adipocyte progress includes various stages such as growth arrest, clonal expansion, 
early differentiation and terminal differentiation (Figure 5).  
 
 
 
 
 
 
Figure 5.  Adipocyte differentiation stages. Pre-adipocytes go into clonal expansion followed by growth 
arrest and characterized by increased levels of C/EBPα and PPARγ. Early differentiation is characterized by 
lipid acquisition, morphological changes, Akt signalling and Pref-1 down-regulation. Terminal 
differentiation is characterized by a merging of lipid droplets to one lipid droplet and expression of late 
markers e.g. GLUT-4.  
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1.2.3.1 Pre-adipocyte lineage  
Characterization of cells as pre-adipocytes refers to cells that preserve the ability to proliferate, 
have a fibroblast-like morphology but are committed to the adipocyte cell lineage 2,68. The main 
difference of pre-adipocytes to other fibroblast like cells that derive from mesenchymal stem 
cells is the presence of pre-adipocyte factor-1 (pref-1) protein. pref-1 is expressed in pre-
adipocytes and its down-regulation is required for the initiation of adipocyte differentiation 69. 
Pre-adipocytes reside in the adipose tissue and can be stimulated to proliferate and/or 
differentiate when it is needed and are retaining this capacity throughout life 70. Tissue 
expansion starts with proliferation of pre-adipocytes that is followed by their differentiation to 
mature adipocytes. Pre-adipocytes are the principal cells in the adipose tissue that have a 
proliferative capacity and ability to differentiate into mature adipocytes 71,72.  
1.2.3.2 Pre-adipocyte cell number regulation  
Regulation of pre-adipocyte number is dependent on the control of the cell cycle. As with other 
cell types, G1 to S phase transition is controlled by growth factors that stimulate the 
downstream expression of CDKs. Insulin-like growth factor have been shown to participate in 
the stimulation of proliferation of pre-adipocytes 73 and also to induce resistance to stress 
factors and apoptosis in these cells. Insulin-like growth factor- binding proteins have also been 
reported to affect pre-adipocyte proliferation 74. Finally hormones such as Thyroxins (T3, T4), 
glukocortikiods, adrenalin, noradrenalin have an impact on the metabolism of adipose tissue 
(lipogenesis and lipolysis).  
1.2.3.3 Growth arrest  
Once cells have reached confluence, cell-cell contact leads to cell cycle arrest. This process, 
however, has been shown not to be required for the differentiation of pre-adipocytes in vitro 44. 
C/EBPα has been shown to regulate the cell growth arrest of pre-adipocytes by p21 mRNA and 
protein expression 75,76. Transcription factor PPARγ can also induce cell growth arrest by 
reducing the DNA binding capacity of E2F/DP 77.  
1.2.3.4 Clonal expansion 
When differentiation is initiated, cell growth- arrested pre-adipocytes need to re-enter the cell 
cycle, at which stage they undergo proliferation known as clonal expansion. Interestingly it has 
been suggested that the molecular pathways for cell cycle proliferation before  and after cell 
growth arrest (clonal expansion) differ 44. Post- confluent pre-adipocyte clonal expansion is 
mediated via changes in the phosphorylation status of Rb and the transient increase of p107 78. 
However, cell cycle arrest that is required before early differentiation and is controlled by the 
expression of C/EBP 72 and is not mediated by Rb and Cdk inhibitors but can take place even 
when Rb is hypophosphorylated 79.  
1.2.3.5 Early differentiation 
Early differentiation stage of adipogenesis is characterized by the up-regulation of several 
transcription factors. Main regulators of adipocyte differentiation C/EBP and PPARγ are 
dramatically increasing during early differentiation stages. Moreover, the anti-adipogenic 
factor that is specific for pre-adipocytes, pref-1, is down-regulated at this stage. During early 
differentiation, cell morphology and ECM composition undergo important changes. More 
specifically, actin and tubulin are reduced 80, while there is a switch in the collagen types with 
an increase of collagen type IV and a decrease of type I and III procollagen and an increase in 
nidogen expression 51,81. Akt signalling is essential for adipogenesis 82,83 and Akt knock-down 
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impairs expression of Krüppel-like factor that is required for completion of adipocyte 
differentiation 84,85.  
1.2.3.6 Terminal differentiation 
The final stages of adipocyte differentiation are characterized by rapid accumulation of lipids, 
mainly TG, fusion of small lipid droplets in to one large lipid vacuole that covers most of the 
cytoplasm of the cell. Terminal differentiation is also accompanied with increased insulin 
sensitivity and expression of perilipin, Glucose transporter type 4 (GLUT-4) and enzymes 
involved in triacylglycerol metabolism 44. ECM re-organization has been shown to be essential 
for terminal differentiation and it has been shown that inhibition of collagen production impairs 
terminal adipocyte differentiation 86.  
 
1.2.4 Macrophages of adipose tissue  
1.2.4.1 Types of macrophages in adipose tissue 
In adipose tissue the majority of immune cells are macrophages, also known as adipose tissue 
macrophages (ATMs). In lean adipose tissue the majority of ATMs are anti-inflammatory 87. 
ATMs are generally classified into two groups, the pro-inflammatory cytokine secreting group 
M1 that is characterized by secretion of e.g. tumor necrosis factor α (TNF-α) that participate in 
the tissues immune defence and the anti-inflammatory cytokine secreting group M2 that secrete 
e.g. IL-4 that are regulating tissue homeostasis and can take part in tissue repair and 
remodelling 88,89. ATMs can be recruited to the site by adipokines secreted from adipocytes 90 
but it has also been shown that resident macrophages are able to proliferate by stimulation with 
IL-4 and do not need to be recruited from the blood stream 91. In obesity, the ratio between 
anti-inflammatory (M2) and proinflammatory (M1) macrophages changes towards the majority 
of macrophages being polarized into M1 pro-inflammatory and this switch is triggered by 
secretion of adipokines from adipocytes as well as from an autocrine system from macrophages 
themselves 88,92–94.  
1.2.4.2 Anti-inflammatory macrophages (M2) 
Anti-inflammatory macrophages (M2) that reside in healthy adipose tissue, are activated by 
PPARγ and are positively regulating insulin-sensitivity 95. Contrary to the popular belief that 
macrophages are hindering adipocyte differentiation and development it has also been shown 
that impairment of pro-inflammatory activation  in mice leads to reduced capacity of tissue 
expansion 57 and it is known that M2 macrophages increase anti-inflammatory cytokines like 
IL-10 and participate in tissue repair 89 M2 macrophages can trigger tissue repair by the 
production of MMPs leading to ECM remodelling, growth factors and cytokines that trigger 
proliferation and differentiation of precursor cells in tissue96 and are responsible for metabolic 
effects such as protection from insulin resistance via production of IL-10 92,95.   
1.2.4.3 Pro-inflammatory macrophages (M1) 
On the other hand, M1 pro-inflammatory macrophages that are recruited and triggered by the 
expression of TNF-α, monocyte chemoattractant protein-1 (MCP-1) and adipokines are 
correlated to BMI and have been shown to contribute to the metabolic syndrome symptoms, 
tissue remodelling, and chronic inflammation 88,89,93,94,97,98.  
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1.2.5 Adipose tissue changes in obesity  
Adipose tissue is now considered an important secretory organ for adipokines that influences 
the function of several organs 99, thus changes in tissue homeostasis or adipose tissue 
malfunctions leads to systemic problems. Obesity has been shown to be associated with an 
increase in the amount of  ATMs  100 presumably due to increased death of adipocytes 101 where 
macrophages gather to remove the dead cells  and hypoxia in the tissue 102 leading to chronic 
low grade inflammation 103. Inflammation in adipose tissue has been shown as the cause of 
several conditions such as cardiovascular disease, atherosclerosis, type-2 diabetes and 
dyslipidemia that all together are referred to as the metabolic syndrome 104. 
Adipose tissue expansion results in secretion of adipokines that will trigger the recruitment of 
macrophages and the ‘phenotypic switch’ of macrophages from anti-inflammatory M2 to pro-
inflammatory M1 macrophages. Increase in pro-inflammatory M1 macrophages is mainly 
regulated by the MCP-1/CCR2 signalling that causes the recruitment of macrophages to 
adipose tissue 105,106. MCP-1 and free fatty acid release (caused by lipolysis) are secreted by 
adipocytes that have become hypertrophic thus triggering the signalling for M1 macrophages 
107 (Figure 6).  
Obesity in adults is mainly characterized by the enlargement of the already existing adipocytes 
(hypertrophic obesity) and in some cases proliferation and increase in the adipocyte number 
(hyperplastic obesity) 108. Hyperplasia is associated with better insulin response and glucose 
metabolism compared to hypertrophy in obesity 109.  Proliferation of pre-adipocytes occurs 
only after the full expansion of adipocytes 110 and cell growth of adipocytes leads to up-
regulation and release of growth factors that can both promote the proliferation of pre-
adipocytes e.g. IGF-I 111.  
 
 
 
Figure 6. Adipose tissue remodelling in obese state. Increase of adipose tissue is characterized 
by increased TNFα, free fatty acids and hypoxia. These changes lead to macrophage recruitment 
and macrophage proliferation and morphological switch form anti-inflammatory m2 macrophages 
to pro-inflammatory M1 macrophages.  
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1.3 TARTRATE- RESISTANT ACID PHOSPHATASE 
1.3.1 TRAP history and properties 
Tartrate- resistant acid phosphatase (TRAP; E.C. 3.1.3.2), also known as purple acid 
phosphatase (PAP),  AcP 5 or uteroferrin (Uf) 112,113 is a diiron centre- containing  
metalloenzyme 114,115. TRAP was initially  described as a member of acid phosphatases in 1954 
by Sundararajan and Sarma 116 and acid phosphatase properties were investigated extensively 
in 1970s 117,118. In 1971, Yam et al. described an isoenzyme of acid phosphatase that was 
tartrate- resistant and  highly expressed in cells from the rare B-lymphocyte-derived hairy cell 
leukaemia 119. During the 1970s and 1980s a variety of studies  described common properties 
for purple acid phosphatase and tartrate- resistant acid phosphatase and in 1990s a study from 
Vincent and Averill proposed that purple acid phosphatase and tartrate resistant acid 
phosphatase were identical 113. TRAP has traditionally been used as a marker for osteoclasts 
and activated macrophages 120–122, however in recent years more functions for TRAP have 
emerged.  
1.3.1.1 TRAP gene and translation  
The gene encoding TRAP (Acp5) is located on chromosome 19p13.2-13.3 in humans 123,124 
and chromosome 9 in mouse 125 and contains five exons of which 4 are translated into protein 
sequences 126,127 while the untranslated exon 1 exists in 3 different variants in mouse (4 in 
humans) with giving rise to 3 mRNA transcripts encoding identical protein sequences but with 
differential cell- and tissue expression patterns  128–130.  
1.3.1.2 Structure-proteolytic cleavage 
TRAP exists in two different isoforms named TRAP 5a and TRAP 5b 131,132. The product from  
translation of the Acp5 gene is the 35 kDa TRAP isoform denoted  5a that can undergo 
proteolytic cleavage giving rise to the dimeric isoform TRAP 5b of ~24 and 16 kDa “subunits”, 
held together by a disulphide bond 133 (Figure 7) . Proteolytic cleavage of TRAP 5a occurs in 
a repressive loop region, Ser145-Val161115,133 by various proteases, such as cathepsins, trypsin 
and papain and is responsible for the increased phosphatase activity of TRAP 5b 133–136. The 
kinetic properties of TRAP are additionally  influenced by the two N-linked oligosaccharide 
chains present in the protein 137.  
Despite the fact that for many years isoform TRAP 5a was considered to serve only as the 
inactive precursor to the enzymatically active isoform TRAP5b, it has recently been apparent 
from several studies that the two isoforms can indeed have different functions and localizations 
and that TRAP 5a has a separate function promoting pre-adipocyte proliferation and 
differentiation and when over-expressed in mice leads to hyperplastic insulin sensitive obesity 
138. 
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1.3.2 TRAP expression and localization  
1.3.2.1 TRAP in macrophages and dendritic cells  
TRAP is expressed by a subset of macrophages 139 140 and dendritic cells 141 and correlates to 
their activation or maturational state. When TRAP is genetically knocked down in mice,  an 
increased basal expression of inflammatory cytokines such as IL-1b, IL-12 and TNFα was 
noted142 while dendritic cells in mice lacking TRAP have increased expression of IL-10 but 
reduced response to T- dependent antigens 143. The expression of TRAP is also regulated by 
cytokines and it has been observed that TRAP is reduced in response to IFNγ and LPS 144 but 
another study indicated increased TRAP expression by LPS 145 and additionally TRAP 
expression is increased by TNFα in monocytes 146  
1.3.2.2 TRAP in bone 
In bone TRAP has been shown to be expressed and secreted by osteoclasts. More specifically, 
TRAP 5a is secreted to the extracellular matrix where it is subjected to proteolytic cleavage 
giving rise to TRAP 5b while intracellular TRAP is found as both isoforms TRAP 5a and TRAP 
5b 133,147,148.  
Apart from osteoclasts, TRAP in bone is expressed by osteoblasts and osteocytes and its 
expression is independent of the osteoclast activity 149–153 but is increased in rats with 
osteoporosis 154. Additionally, when TRAP is over-expressed in mice there is increased bone 
mineral content and density that stems from increased osteoblast differentiation since 
resorption activity remains stable 155 indicating a function of osteoblast TRAP different than 
that of osteoclast TRAP. TRAP in osteoblasts is located in LAMP-1 positive vesicles thus 
exhibiting lysosomal localization 156.  
Figure 7. Proteolytic cleavage of TRAP 5a generates TRAP 5b. TRAP 5a is cleaved by proteases in a 
repressive loop that generates the “dimer” TRAP 5a held together by disulphide bonds and leading to 
changes in the di-iron centre increasing the phosphatase activity of the protein.  
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Finally TRAP has been shown to be expressed in cartilage by hypertrophic chondrocytes 156. 
This may explain the cartilage phenotype observed in TRAP-deficient mice where the growth 
plate displayed increased height and disorganized columns of chondrocytes 157. TRAP 
expression from chondrocytes and osteoblasts is of interest since they share a common 
mesenchymal stem cell lineage and particularly since TRAP expression in cells of the same 
lineage such as pre-adipocytes is very low 158, indicating a regulation of TRAP expression 
potential during commitment to different lineages.  
1.3.2.3 TRAP expression from other cell types 
Apart from the immune system and bone where TRAP expression has been extensively studied, 
TRAP expression has been observed in other cell types such as neurons 159, hepatocytes and 
keratinocytes 160.  
1.3.2.4 TRAP binding partners 
TRAP has been shown to interact with heparin 148,161,162 and heparin has been shown to inhibit 
activity of TRAP 5a but not TRAP 5b 163 . TRAP has also been suggested to interact with the 
HPSG glypican-4 in bone 164 and with the TGFβ receptor interacting protein 1 (TRIP-1) 
152,165,166. In serum, TRAP has been shown to be associated to α2-macroglobulin in a calcium-
dependent manner 167.  
 
1.3.3 TRAP in disease 
1.3.3.1 TRAP 5a vs. TRAP 5b as disease markers  
TRAP 5a and TRAP 5b have been suggested to have different localizations and serve as 
markers to different pathological conditions, where TRAP 5b has been shown to be a marker 
for osteoclast number and bone resorption in serum 133120–122 and end-stage renal disease 168 
and kidney failure. On the other hand TRAP 5a has been suggested as a marker for mostly 
inflammatory conditions 169, such as atherosclerosis  170, rheumatoid arthritis, 171,172 and 
sarcoidosis 173.  
1.3.3.2 TRAP and autoimmunity 
Besides expression TRAP in certain macrophages, also certain dendritic cells known to be 
involved in antigen presentation, have been shown to be express TRAP with a proposed role 
in dendritic cell maturation142. Knock-down of TRAP in mice and in humans with inactivating 
mutations in the TRAP gene show a similar deregulated immune phenotype with increased 
basal expression of Th1 cytokines such as Interferon-γ (IFNγ), TNFα and IL-1142,174. This 
aberrant immune response was coupled to increased phosphorylation of osteopontin, a protein 
with known function to control TH1/Th2 bias through dephosphorylation by TRAP 175–177. 
1.3.3.3 TRAP in cancer 
TRAP has also been shown to be elevated in melanoma, gastric, colon, ovarian and breast 
cancer 178–183 and when over-expressed in  a human breast cancer cell line, TRAP 5a and TRAP 
5b can be found intracellularly while only TRAP 5a is secreted 184. Moreover, TRAP has been 
shown to increase invasion and metastasis of cancer cells, to increase their migration and 
change their morphology and adhesion pattern 185. In contrast, siRNA transfection revealed a 
morphological effect consistent with impaired detachment to plastic-bound substrates 186.   
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1.3.4 Regulation of cell number and differentiation by TRAP 
TRAP has been shown to have effects on cell proliferation and differentiation 152,155. In bone 
tissue TRAP has been shown to give rise to increased cortical bone mineral density and content 
and increased expression of bone differentiation markers when over-expressed 155 in mice and 
to have an effect on differentiation of osteoblasts 165,187 and to interact with the TGF-β-receptor-
interacting protein (TRIP-1) that exerts a TGF-β like differentiation 152,166. Osteoblast-like cells 
have also exhibited the ability to both express and endocytose TRAP 151,153 and TRAP levels 
are altered during osteoblast differentiation 187. However, the exact function of TRAP 
expression and endocytosis by osteoblast-like cells in bone is not known.  TRAP has 
additionally been shown to have an effect on cell number regulation of hematopoietic cells and 
to be a regulator of fetal erythropoiesis by acting synergistically with erythropoietin and other 
growth factors 188,189.  
 
1.3.5 Regulation of migration by TRAP 
Apart from cell number regulation TRAP has been shown to affect the motility, morphology 
and migration of cancer cells 185. In osteoclasts, TRAP exhibits phosphatase activity with 
osteopontin as substrate 175,176 and dephosphorylation of osteopontin leads to reduced 
attachment of osteoclasts and changes in migration 190,191.  
 
1.3.6 TRAP 5a in adipose tissue  
Interestingly, isoform TRAP 5a has been shown to be involved in the regulation of the adipose 
tissue. In 2008, Lång et al. showed that when TRAP 5a is overexpressed in mice, it leads to 
hyperplastic insulin- sensitive obesity and that human and mouse pre-adipocytes show 
increased proliferation and differentiation by the addition of TRAP 5a but not 5b 138. 
Additionally, no signs of inflammation were observed in the TRAP 5a over-expressing mice 
138.  
In adipose tissue, TRAP 5a has been shown to be elevated in obese individuals 192 and an 
increase of TRAP 5a has been described in the serum of overweight young males 193. However, 
unlike other inflammatory markers, its expression was not reduced after exercise and weight 
loss 193. TRAP expression in different adipose tissue depots also changes with obesity. In lean 
individuals TRAP levels are higher in visceral, while in overweight and obese individuals, 
higher levels of TRAP are observed in subcutaneous fat depot 98. TRAP 5a expression and 
secretion in the adipose tissue is almost exclusively from macrophages 138,192 and even though 
TRAP 5a and TRAP 5b are both found intracellularly in ATMs, TRAP 5a is the only isoform 
that gets secreted 192. Additionally, TRAP levels co-related to both number and size of 
adipocytes as well as with TNFα and IL-6 192.  
TRAP 5a secretion by macrophage suggests a paracrine action where TRAP 5a is secreted by 
macrophages but can act on pre-adipocytes and affect their proliferation and differentiation. 
However, until now little is known on the mechanism of action of TRAP 5a on cells in order 
to regulate cell number, differentiation and migration as well as its binding partners on the 
extracellular environment and cells. 
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1.3.7 Working hypothesis  
The working hypothesis of this thesis was that TRAP 5a is secreted by a subset of macrophages 
in the adipose tissue, where it is presented to pre-adipocytes for binding to the cell surface and 
initiation of signalling pathways that can promote proliferation, differentiation and further 
effects in pre-adipocytes (Figure 8). However the molecular pathways, binding partners and 
secretion patterns of TRAP 5a in adipose tissue remain to be explained. In this thesis, the aim 
was to shed light on different aspects of TRAP 5a action in adipose tissue such as expression 
levels related to BMI, interaction of TRAP 5a with binding partners in ECM and cell surface, 
signalling pathways and functional effects in pre-adipocytes. 
 
 
  
Figure 8. Working hypothesis of TRAP 5a mechanism of action in adipose tissue. TRAP 5a 
secreted from macrophages acts on pre-adipocytes in order to stimulate proliferation and differentiation 
a well as possible unknown effects.  
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2 AIMS OF THE THESIS 
 
Paper I. The aim was to develop a human TRAP 5a specific ELISA in order to evaluate levels 
of TRAP 5a from obese vs. lean individuals.  
 
Paper II.  The aim was to identify potential binding partners of TRAP 5a in adipose tissue.  
 
Paper III.  The aim was to investigate the interaction between TRAP 5a and pre-adipocytes, 
the binding mechanism on the cell surface, endocytosis routes and interaction with other cell 
types of mesenchymal lineage.  
 
Paper IV. The aim was to investigate the effect of TRAP 5a in the regulation of pre-adipocyte 
cell number, differentiation and migration and identify potential signalling pathways through 
which TRAP 5a action occurs.  
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3 REMARKS ON METHODOLOGY 
 
3.1 TRAP 5A ELISA DEVELOPMENT 
For ELISA development, the first step was the generation of monoclonal antibodies specific 
for human TRAP 5a. To achieve this, the peptide loop region present on human TRAP 5a but 
not human TRAP 5b was used as the immunogen by which mice were immunized. Apart from 
TRAP 5a antibodies, antibodies against total TRAP (TRAP 5a+TRAP 5b) were developed. To 
achieve this, the full length protein was used. Next, isolated antibodies were epitope mapped 
by ELISA. Epitope mapping of antibodies allows the grouping of antibodies for further use in 
a sandwich ELISA. The use of antibodies from different epitopes increases the possibility of 
both capture and detection antibodies to bind to the protein with high affinity and no 
interference of binding from one to the other. 
 One aspect of the quality assessment of the newly developed ELISA was the effect that serum 
components can possibly have on the detection of TRAP 5a. For this purpose recombinant 
TRAP 5a was diluted in serum in a dose- dependent manner and absorbance was measured.  
The sandwich ELISA was evaluated by measuring absorbance in a TRAP 5a dose response, 
testing of TRAP 5b absorbance and measuring intra- and inter- assay variation and reference 
interval in a set of human serum samples from healthy males to verify the reproducibility of 
the results.  
 
3.2 PULL DOWN ASSAYS  
In paper II, the potential binding of TRAP 5a to nidogen-2 and TRIP-1 were studied in vitro 
using recombinant proteins in pull- down assays. In this system, His-tagged proteins were used 
as bait. The property of the His-tag to bind to Ni was used to bind the ‘bait’ proteins in magnetic 
agarose- Ni beads that could then be pulled-down by magnet. Ni- beads often exhibit 
considerable unspecific binding of proteins and a way to address this is saturation of beads with 
His-peptides to be used as control. In the pull- down assays described, control beads (beads 
with no His-tagged recombinant protein) were saturated with His- peptides to prevent 
unspecific binding.  
One other important aspect to be taken into account when performing pull- down assays was 
the stoichiometry between the recombinant proteins that are studied. In the pull-down assays 
between His-tagged nidogen-2 domains and TRAP 5a, stoichiometry was always 1:1 for ‘bait’ 
and protein of interest.  
 
3.3 ICC/ 2-STEP INDIRECT STAINING  
To investigate if TRAP 5a can bind to the surface of pre-adipocytes, immunocytochemistry 
and indirect staining was used, where cells were treated with TRAP 5a for 1h and then fixed 
with formalin or aceton. After fixation cells were incubated with primary antibody against 
TRAP and fluorescent secondary antibody. The staining observed reflected only bound TRAP 
5a since no TRAP 5a was detected in untreated cells. Since the potential binding partner for 
TRAP 5a was unidentified, to study binding of TRAP 5a cells were treated with TRAP 5a at 
4°C to minimize endocytosis, thus ensuring that TRAP staining will only reflect TRAP 5a 
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bound to the surface. For the same purpose immunocytochemistry was performed without cell 
membrane permeabilization. Immunocytochemistry was followed by image analysis.  
 
3.4 IMAGE ANALYSIS 
In paper II, immunocytochemistry, proximity ligation assay and immunohistochemistry was 
used to evaluate nidogen-2 expression, interaction of TRAP 5a with nidogen-2 and TRIP-1 and 
co-localization of TRAP 5a with nidogen-2 in adipose tissue, respectively.  
Image analysis was performed as follows: For proximity ligation assays the number of positive 
spots (each spots corresponds to an interaction site) were counted using Volocity software and 
divided with the area of each cell. For immunohistochemistry, co-localization was also 
quantified and analysed. In this case, co-localization was measured using Volocity software to 
calculate Pearson’s correlation between the two colours (green for TRAP 5a and red for 
nidogen-2) as well as overlap coefficient M1 and M2 for the two channels, in five regions of 
interest. An important aspect of image analysis in order to generate Pearson’s correlation and 
M1 and M2 values is setting threshold for signal. In all image analysis threshold was set by 
negative control of one of the two proteins, in order to minimize false positive co-localization. 
In adipose tissue, section that have not been stained for nidogen-2 served as negative control 
for threshold setting.  
Overlap co-efficient refers to the amount of overlap of one channel towards the other, for 
instance M1 overlap coefficient refers to the amount of overlap of green channel to the red 
channel, while M2 refers to the overlap of red channel to the green channel. This is important 
in order to identify if two proteins are always co-localized (high M1 and M2 values) or if only 
one protein is always co-localized to the other (high M1 value but low M2 or vice versa) but 
the other one can be also observed in other areas.  
Image analysis was also performed in immunocytochemistry and co-localization studies (paper 
III) following the same principles as described above. Since these studies were performed using 
pre-adipocytes, threshold was set for pre-adipocytes that had not been treated with TRAP 5a. 
Pre-adipocytes do not express TRAP 5a thus if not treated with TRAP 5a, no staining should 
be observed. This property can thus serve as a negative control. In this paper, quantification of 
ICC was also performed using velocity software and quantifying the number of clusters/area. 
For the quantification of clusters, parameters such as circularity, size and intensity of 
spots/clusters were standardized using TRAP 5a treated cells as a positive control. Data 
collected in the above method were statistically analysed in 4-10 cells using non-parametric 
Mann-Whitney U-test.  
 
3.5 CELL CYCLE ANALYSIS 
In paper IV, proliferation was studied by cell cycle analysis using the Bromodeoxyuridine 
(BrdU) incorporation method in combination with FACS analysis. This was performed in cells 
that were allowed to enter the cell cycle and left for various time points to progress in the cell 
cycle before BrdU was added. BrdU analysis can be performed in two manners (1) BrdU is 
added immediately after cell cycle entry and is incorporated into the DNA for several hours 
before cell fixation, staining and FACs analysis or (2) BrdU is added at various time points 
only for a short period of time before cell fixation. In the first case, BrdU incorporation is a 
measurement of the percentage of cells that have engaged in cell cycle entry immediately after 
serum stimulation and until the time of fixation, thus giving an overview of the total number of 
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cells undergoing cell cycle progress. On the other hand, in approach (2), BrdU incorporation 
occurs briefly and only to cells that undergo S phase at the moment of BrdU addition and not 
the total amount of cells that have undergone G1 to S transition. In this study the second 
approach was used where BrdU incorporation reflects the number of cells in S phase 
momentarily and throughout the whole time course. This approach was selected in order to 
evaluate at which time point TRAP 5a effect takes place without masking the effect from the 
accumulation of cells in the S phase.  
The selection of BrdU for studying proliferation was based on two reasons. Firstly, BrdU 
incorporation in combination with propidium iodide (PI) can give a clear separation of the cell 
cycle stages G1, S and G2/M thus allowing for a detailed comprehension of the cell cycle and 
TRAP 5a effects. Second, viability assays broadly used for proliferation studies (e.g. XTT 
assay) are based on mitochondrial activity. Since TRAP 5a effects on cells are under 
investigation, it cannot be excluded that TRAP 5a alters the mitochondrial activity of the cells 
thus affecting the read-out of assays based on this type of activity.  
  
3.6 PHOSPHORYLATION SIGNALLING ASSAYS 
In paper IV, in order to investigate signaling assays triggered by TRAP 5a upon cell cycle 
entry, a signalling array detecting alterations in phosphorylation status was used. Since 
phosphorylation status of proteins involved in the cell cycle regulation occur very fast, the time 
points selected ranged between 5-30 min.  
 
 
  23 
4 RESULTS AND DISCUSSION 
4.1 PAPER I  
In this study the aim was to develop a human TRAP isoform 5a- specific ELISA that would 
give the possibility of studying TRAP 5a levels in serum. Here,  obese vs. lean individuals was 
compared in order to assess if TRAP 5a correlates to BMI in serum as previously reported 193.  
Firstly we developed monoclonal  antibodies (mAbs) specific for TRAP 5a using the loop 
present in TRAP 5a but absent in TRAP 5b due to proteolytic cleavage 131 as well as  mAbs 
detecting both isoforms using the full length protein. Epitope mapping allowed grouping the 
mAbs according to the recognition epitope. Three groups of mAbs were identified for total 
TRAP (TRAP 5a+5b) one of which was mAb with the peptide loop as recognition epitope 
(mAb 46). Results showed that TRAP 5a could successfully be recognized by the specific mAb 
46 both in Western immunoblot and ELISA and that a mAb (clone 12.56) raised against full 
length TRAP could recognise both isoforms.  With the combination of a mAb against TRAP 
5a (mAb 46) as capture antibody and a mAb against total TRAP (mAb 12.56) as detection 
antibody, the development of an ELISA was possible. Even though, antibodies specific for 
TRAP 5a have been developed and used in the past 194,195, this is the first time that mAb against 
TRAP 5a has been raised using the peptide loop present only in TRAP 5a, instead of subcloning 
which could potentially increase the specificity of an  ELISA since it is assured that the 
recognition epitope is only present on isoform TRAP 5a. 
After evaluation of mAbs, the ELISA was validated for isoform specificity using TRAP 5a and 
TRAP 5b isoforms and it was shown that with the combination of antibodies mAb 46 (TRAP 
5a) and mAb 12.56 (TRAP 5a+5b) only TRAP 5a was detected and absorbence was dose-
dependent with a lower detection limit of 0.112 ± 0.039± ng/ml. Since TRAP has previously 
been shown to associate with α2-macroglobulin in serum 167, the effect of serum in the dose-
dependent response for TRAP 5a was evaluated by the use of commercially available serum 
samples. Hence it was shown that serum has no effect on TRAP concentrations up to 0.5ng/ml 
in the standard curve. At higher TRAP 5a concentrations, serum had an inhibitory effect on the 
absorbance which could be due to failure to completely dissociate complexes of TRAP 5a with 
serum components.  
Inter- and intra-assay variation of TRAP were evaluated in a set of commercially available 
serum samples (3 samples for intra-assay and 17 samples for intra-assay) from healthy males. 
Intra-assay variation was calculated in average to 10.3% and inter-assay variation to 10.7% that 
are both in acceptable ranges for an ELISA assay. Apart from variations, the reference interval 
was calculated to 0.86-6.27 ng/ml while the mean concentration was 3.65±1.23 ng/ml. The 
mean concentration for healthy males is in the same range as reported  previous studies where 
TRAP 5a was measured and have shown that mean TRAP 5a concentration in serum of healthy 
males was 2.65 ± 0.29 ng/ml 193 and 5.89 ± 1.65 ng/ml 195 in different groups of healthy males.  
After validation of the newly developed ELISA, TRAP 5a ELISA was used to measure the 
levels of TRAP 5a in serum from lean vs. obese females. The same groups were used to 
measure total TRAP with a previously described ELISA 192 in order to evaluate if the 
relationship between the groups is the same for TRAP 5a and total TRAP. The mean 
concentration for TRAP 5a of lean individuals was calculated to 3.78 ng/ml and to 1.97 ng/ml 
for obese females using the newly developed TRAP 5a ELISA indicating that TRAP 5a levels 
were lower in obese individuals compared to lean. These findings seem to be in contrast with 
what has been observed in a previous study where TRAP 5a was elevated with increased BMI 
193. However in this previous study the group investigated was overweight and male rather than 
obese (BMI=25-30 kg/m2) while in this study all individuals in the female obese group had a 
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BMI of over 30 kg/m2. The same relation between lean and obese group was also indicated 
when total TRAP was measured, where the mean concentration for the lean group was 1.19 
ng/ml and for the obese group 0.79 ng/ml. Despite the fact the two assays seem to decline in 
terms of absolute values, they seem to exhibit the same relation for TRAP levels between lean 
and obese group.  
Finally, it was investigated whether there is a correlation between TRAP 5a and total TRAP 
levels with BMI for the group of lean and obese individuals. A significant correlation was only 
observed between TRAP 5a and BMI in the group of obese individuals, thus indicating that in 
lean individuals, multiple factors apart from the adipose tissue burden can contribute to the 
levels of TRAP 5a. In the study by Shih et al. in 2010 193, correlation was observed in a group 
of individuals with BMI of 18.5-30 kg/m2 however no separation between lean and overweight 
group was performed.  
In summary, in paper I the development and validation of a new ELISA for detection of TRAP 
5a isoform is described, with the use of monoclonal antibodies raised against the peptide loop 
present in TRAP 5a but not TRAP 5b (for TRAP 5a specific mAb) or the full length protein 
(for total TRAP mAbs), its evaluation using serum from healthy males and its use to detect 
TRAP 5a levels in serum from obese and lean females. Results showed a decreased TRAP 5a 
expression in the serum of obese (BMI≥30 kg/m2) vs. lean females and correlation between 
TRAP 5a and BMI only in the obese group, perhaps indicating that  only in obesity TRAP 5a 
levels are mainly determined by adipose tissue. It has also been shown that expansion and 
morphology of adipocytes in different depots (hyperplasia vs. hypertrophy) plays a role in the 
metabolic profile 109 and also that TRAP highest expression shifts from visceral in lean to 
subcutaneous in obese individuals 98, thus indicating that the depot and morphology of adipose 
tissue could also influence the serum levels.  
 
4.2 PAPER II 
The aim of this study was to identify potential binding partners for TRAP 5a in the adipose 
tissue and to investigate if the previously suggested binding partner for TRAP, i.e. TRIP-1 
152,165 is interacting with TRAP 5a in pre-adipocytes. For this purpose, cell membrane proteins 
from pre-adipocytes were isolated and used in a pull-down assay were His-tagged TRAP 5a 
was used as ‘bait’.  
After pull- down assay, 3 bands with molecular weight higher than TRAP 5a were observed 
by SDS-PAGE and silver staining and were analysed using mass spectrometry. All three bands 
contained a peptide sequence corresponding to protein nidogen-2. This finding was initially 
surprising since nidogen-2 is not known to be found on the membrane of cells, however, this 
could be due to nidogen-2 attaching to the cell surface via its RGD-region 196 and thus being 
isolated together with membrane proteins. Nidogen-2 has originally been shown to be an ECM 
protein and to have a high homology with nidogen-1 197 while its expression is up-regulated 
during adipocyte differentiation 52, thus it was hypothesized that nidogen-2 could bind TRAP 
5a after  secretion of the latter from macrophages in the ECM in an interaction module similar 
to what has been observed for growth factors e.g. for HGF interaction with vitronectin and 
fibronectin 198.  
Firstly, nidogen-2 mRNA and protein expression in pre-adipocytes and differentiating pre-
adipocytes was investigated and it was shown that indeed mRNA expression of nidogen-2 is 
up-regulated during differentiation. Nidogen-2 was detected both in media and cell lysate of 
pre-adipocytes, however a large fraction was of lower molecular weight than full length 
nidogen-2, indicating  a proteolytical processing event in one of its cleavage sites 199. 
  25 
Localization of nidogen-2 in pre-adipocytes was investigated by immunocytochemistry and 
this protein was shown to be located in cytoplasmic vesicles and fiber-like structures, while in 
previous studies nidogen-2 was observed pericellularly 199. Since identification of nidogen-2 
by mass spectrometry had very low coverage, additional methods were used to verify if indeed 
it interacts with TRAP 5a. Pull down-assays were used with either His-tagged TRAP 5a or His-
tagged nidogen-2 as ‘baits’ and untagged nidogen-2 or untagged TRAP 5a respectively. 
Nidogen-2 contains three distinct domains G1, G2 and rod-G3 with different binding motifs 197 
and pull- down assays with the different domains were also used to evaluate which domain of 
nidogen-2 mediates the binding to TRAP 5a. Results showed that TRAP 5a could pull down 
nidogen-2 and that nidogen-2 rod G3 domain was responsible for the interaction between 
TRAP 5a and nidogen-2, thus further verifying that the potential interaction between the two 
proteins. Since nidogen-2 was shown to be localized to vesicle- and fibre- like structures in 
pre-adipocytes, it was investigated whether there existed a potential interaction of nidogen-2 
with TRAP 5a. For this purpose, proximity ligation assay was performed in pre-adipocytes that 
had been treated with TRAP 5a, a showing that TRAP 5a and nidogen-2 are indeed interacting 
in pre-adipocytes. The interaction between nidogen-2 and TRAP 5a could occur in endocytic 
vesicles by endocytosis of TRAP 5a from the ECM, in complex with nidogen-2 fragments. 
Finally, the localization of TRAP 5a in relation to nidogen-2 in adipose tissue was investigated 
and it was shown that the two proteins are co-localized in vesicles in adipose tissue cells, 
indicating a potential interaction.  
Apart from the interaction of nidogen-2 and TRAP 5a, the previously suggested binding partner 
for TRAP 5a, i.e. TRIP-1 was investigated for interaction with TRAP 5a in pre-adipocytes. 
This showed that TRIP-1 and TRAP 5a interact in vitro in a pull- down assay system and 
intracellularly in pre-adipocytes. Interaction between the two proteins intracellularly in vesicles 
was surprising since TRIP-1 has been suggested to be localized in the cytoplasmic matrix and 
nucleus 200 while TRAP 5a is not expressed by pre-adipocytes but only endocytosed and thus 
most likely located in endocytic vesicles.  
In summary, this study aimed to identify new binding partners for TRAP 5a in pre-adipocytes 
and to investigate the previously suggested interaction of TRAP with TRIP-1 with the use of 
pull down and proximity ligation assays. Results revealed nidogen-2 as a potential binding 
partner of TRAP 5a intracellularly in pre-adipocytes and in adipose tissue and indicated that in 
pre-adipocytes TRAP 5a can interact with TRIP-1 intracellularly.  
 
4.3 PAPER III 
The aim in this paper was to determine if TRAP 5a can interact with the cell surface of pre-
adipocytes and to investigate the routes through which TRAP 5a gets endocytosed by the cells. 
We also aimed to investigate TRAP 5a interaction with heparin and heparan sulfate and with 
the HPSG glypican-4 that has previously been suggested to interact with TRAP in bone 164.  
Firstly, pre-adipocytes were treated with TRAP 5a and TRAP 5b at 4°C to prevent endocytosis 
and using immunocytochemistry and electron microscopy it was shown that TRAP 5a but not 
TRAP 5b can bind to the plasma membrane of the cells in a dose- dependent manner as shown 
by FACS. The staining revealed a spot-like pattern that could indicate the formation of receptor 
clusters, a process known to be used by some receptors for activation 201. When the same 
method was applied at 37°C where endocytosis is allowed, TRAP 5a was shown to be 
endocytosed in a dose- dependent manner. Interestingly, no TRAP 5a endocytosis was 
observed for differentiated adipocytes, indicating that the expression of a binding partner for 
TRAP 5a in pre-adipocytes is down-regulated during differentiation.  
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Using gel filtration chromatography and activity assays, it was shown that TRAP 5a forms 
complexes with heparin and heparan sulfate, however only heparin was able to inhibit TRAP 
5a phosphatase activity. The binding of TRAP 5a to heparan sulfate is of particular interest 
since a lot of proteins that can have a mitogenic effect mediate their effect through binding to 
heparan sulfate in the ECM and cell surface, e.g. FGF2 binding to FGF2 receptor leads to 
dimerization that is regulated by binding to heparan sulfate 202–204.  
Co-localization between Glypican-4 and TRAP 5a  was addressed and it was shown that TRAP 
5a was co-localized with glypican-4 on the cell surface membrane and on endocytic vesicles, 
indicating that TRAP 5a could potentially bind to the cell membrane using the HPSG glypican-
4 as a co-receptor for signalling and/or endocytosis facilitation as observed for other glypicans 
and their ability to bind to growth factors and facilitate signalling from the cell surface 205,206. 
As described above, TRAP 5a was shown to bind to pre-adipocyte cell surface and found in 
intracellular vesicles so next we aimed to investigate the endocytosis route of TRAP 5a. 
Proteins that act as growth factors or mitogens have been shown to follow to major pathways 
of endocytosis. i.e. the clathrin- or caveolae- mediated pathways that are both dependent on 
dynamin. Firstly we questioned if a dynamin inhibitor could prevent endocytosis and it was 
shown that TRAP 5a endocytosis is indeed dynamin- dependent. Subsequently, using clathrin- 
and caveolae- specific inhibitors it was shown that TRAP 5a endocytosis is caveolae-mediated, 
which is an endocytosis route used only by a few growth factors since most growth factors are 
endocytosed in a clathrin-dependent manner 207. Interestingly, it has been shown that caveolae-
mediated endocytosis is responsible for insulin signalling 208 and that triacylglycerol synthesis 
takes place in the caveolae 209, thus indicating that TRAP signalling could potentially act in a 
similar manner.   However this could also depend on the concentration of TRAP 5a used, as in 
this study 100M were used- a quite excessive concentration and it has previously been reported 
that cell could use caveolae- dependent endocytosis in the presence of high concentrations of 
growth factors to target them to degradation, e.g. EGF that at low concentrations is endocytosed 
in a clathrin- mediated manner but at a high concentration instead by a clathrin- independent 
manner 10.  
TRAP 5a was shown to co-localize with the late endosomal marker Rab-7 and by electron 
microscopy to be also found in multivesicular bodies. However, it did not co-localize with the 
lysosomal marker LAMP-1, indicating that TRAP 5a either does not end up in the lysosomes 
or that it is degraded rapidly thus it is not detected, unlike what has been observed for TRAP 
in osteoblasts that co-localizes with LAMP-1156, probably due to the different routes followed 
by the two cell types for TRAP processing since TRAP is expressed endogenously in 
osteoblasts 149–153 but not in pre-adipocytes 138.  
Finally, mesenchymal stem cells and pre-osteoblasts and fibroblasts (that are also of 
mesenchymal lineage) were studied for their ability to bind TRAP 5a and it was shown that 
pre-osteoblasts but not MSCs or fibroblasts had the ability to bind TRAP 5a. TRAP 5a binding 
by pre-osteoblasts is in line with previous findings that indicate that pre-osteoblasts are able to 
bind TRAP 153. Apart from pre-adipocytes TRAP 5a was shown to bind to pre-osteoblasts but 
not fibroblasts or mesenchymal stem cells.  
In summary, this study aimed to identify if TRAP 5a binds to cell surface on pre-adipocytes 
and the route of endocytosis thereafter as well as to investigate if TRAP 5a colocalizes with the 
previous suggested binding partner glypican-4 and interaction with heparin and heparan 
sulfate. Results showed that TRAP 5a but not TRAP 5b binds to the cell surface of pre-
adipocytes, gets endocytosed in a caveolae- dependent manner and ends-up in late endosomes 
and mulivesicular bodies. Additionally it was shown that TRAP 5a forms complex with heparin 
and heparan sulfate and colocalizes with the HPSG glypican-4. 
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4.4 PAPER IV  
The aim of paper IV was to investigate the effect of TRAP 5a exposure, mimicking a paracrine 
situation, on cell cycle, differentiation and migration of pre-adipocytes and to identify potential 
signalling pathways affected by TRAP 5a treatment in pre-adipocytes shortly after cell cycle 
entry.  
Firstly, cells were incubated with serum- free media for cell cycle arrest and synchronization 
and then they were allowed to enter the cell cycle in the presence or absence of TRAP 5a. 
Results indicated an increased number of cells in the S phase after 12h (~50% more cells) and 
increased cyclin D1 expression.  
Cyclin D1 expression is an important hallmark in cell cycle progression as it signifies the G1 
to S transition 24 and is regulated by intracellular signals such as e.g. GSK3β inactivation 22,23 
by activated Akt [40] or by Wnt- mediated signalling 26, thus next we aimed to screen for 
potential phosphorylation changes in proteins of the Akt signalling pathway using a protein 
phosphorylation array. Interestingly results showed a decreased phosphorylation in Akt and 
Erk sites responsible for its activation suggesting that perhaps the action of TRAP 5a on cell  
number regulation  is not mediated via direct activation of Akt or that TRAP 5a leads to faster 
response by the cells and transient activating phosphorylations of Akt 20 to be already down-
regulated already after 5 min.  
On the other hand, GSK3β showed reduced phosphorylation that leads to its inactivation and 
subsequent β-catenin stabilization that could account for effects on e.g. cyclin D1 levels and 
anti-apoptotic genes 34,210,211. Apart from Akt, GSK3β regulation is mediated via canonical and 
non-canonical pathways of Wnt signalling 210 that is also involved in cell cycle entry and 
apoptosis reduction 34 and thus could be a potential signalling pathway affected by TRAP 5a. 
Stat3 activating phosphorylation was shown to be increased by TRAP 5a treatment and Stat3 
has been shown to have an effect on the proliferation of pre-adipocytes, cyclin D1 levels and 
anti-apoptotic genes 212,213. After serum addition and cell cycle entry an up-regulation of 
phosphorylations leading to activation of pro-apoptotic proteins p53 and p38 in control cells 
was observed. Increased  activity of pro-apoptotic proteins could be attributed to 
hypermitogenic stimulation28. Interestingly,  p53 and p38 exhibited reduced activating 
phosphorylation and Bad exhibited increased inhibiting phosphorylation after TRAP 5a 
treatment, indicating a potential effect of TRAP 5a in genes regulating cell cycle arrest and 
apoptosis, a mechanism that could also be involved in the cell number regulation as the ‘break’ 
in cell cycle progression.  Activating phosphorylation of HSP27 that is involved in cell cycle 
arrest and is a downstream target of p38 214,215 was also observed after TRAP 5a treatment, 
further suggesting a p38- and p53- mediated effect of TRAP 5a in cell cycle arrest. When p38 
is activated cyclin D1 is inhibited thus leading to cell cycle arrest, while p53 is increased 
leading to p21 activation that results in cell cycle arrest or p16, p14/p19 activation resulting in 
premature senescence 216–218. In this system, cells have been serum- deprived and cell cycle- 
arrested, thus a reduced activation of p38 and p53 would likely indicate an increased evasion 
of the cell cycle arrest after serum stimulation.  
Proteins p38, p53 and heat shock protein 27 (HSP27) have been shown to  effect several 
biological events, such as migration 215,219–222, which can be also coupled to proliferation. This 
idea is contrary to previous beliefs that proliferation and migration are two separate events that 
cannot take place simultaneously 223,224. Since TRAP has  previously been shown to have an 
effect on the migration of osteoclasts 225 and migration and morphology of cancer cells 185, we 
investigated the effect of TRAP 5a on morphology, migration and protein expression of 
proteins related to migration adhesion and cell shape such as focal adhesion kinase (FAK), 
paxillin and actin. Morphological analysis and wound healing assay showed that TRAP 5a lead 
to less circular and more elongated cells and increased migration. Also, synchronized pre-
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adipocytes were assessed for morphology after serum stimulation in the presence of TRAP 5a 
and it was shown that cells became larger at low concentrations of TRAP 5a but less circular 
and more elongated at high concentrations. Protein expression of FAK and paxillin was 
decreased after 8h of TRAP 5a treatment, whereas β-actin was decreased after 5h, indicating 
that apart from morphology, TRAP 5a could exert an effect on the adhesion pattern of the cells.  
Finally, the effect of TRAP 5a in early differentiation of pre-adipocytes was tested and it was 
shown that TRAP 5a enhances lipid droplet acquisition already after 2 days of differentiation 
independently of stimulation by the PPARγ activator rosiglitazone. The mechanism through 
which differentiation is affected by TRAP 5a remains unknown, however since pro-apoptotic 
proteins have been shown to have an effect on pre-adipocyte differentiation and differentiating 
pre-adipocytes exhibit increased resistance to apoptosis 226 it is likely that pre-adipocyte 
differentiation is stimulated by TRAP 5a via the same signalling pathway responsible for 
augmented G1 to S transition.  
In summary, this study aimed to investigate the outcome of TRAP 5a treatment on pre-
adipocytes and it was shown that TRAP 5a enhances the proliferation, migration and 
differentiation of pre-adipocytes. In a protein level, TRAP was shown to increase cyclin D1 
levels and to change the phosphorylation pattern of GSK3β and to decrease activating 
phosphorylation of pro-apoptotic proteins p53 and p38. Finally, TRAP 5a was shown to affect 
cell morphology and reduce the expression of β-actin, FAK and paxillin. These results suggest 
an overall effect in the cell cycle events by TRAP 5a that could possibly be mediated by a 
common pathways affecting GSK3β activity.  
. 
4.5 GENERAL CONCLUSIONS AND DISCUSSION  
In paper I it was shown that serum levels of TRAP 5a from obese females are lower than those 
from lean females. As discussed earlier, this was an interesting finding since TRAP levels in 
adipose tissue of obese women are elevated 192. This could indicate different processing 
mechanisms of TRAP 5a from adipose tissue in lean and obese states. TRAP 5a expression is 
increased but perhaps the deposition to the serum could be reduced and more TRAP 5a remains 
associated to the tissue where it can stimulate the proliferation and differentiation of pre-
adipocytes. Also since TRAP 5a has been shown to be endocytosed by pre-adipocytes in paper 
II, TRAP 5a levels in adipose tissue could be maintained high by endocytosis in the tissue. It 
has been shown that the size of adipocytes and type of obesity (hyperplastic vs. hypertrophic 
obesity) in visceral and subcutaneous depots is important for the expression levels of cytokines 
as well as for the metabolic effects  109, so the depot and type of obesity could also be related 
to the TRAP 5a levels in serum. Decreased levels of tissue in the serum of obese women seems 
also contradictory to a study performed in Chinese overweight males where it was shown that 
TRAP 5a is elevated in males with BMI 25-30 kg/m2193. However, as discussed earlier the 
study of paper I differs from the previous study in the BMI grouping (study I was performed 
in a group of obese females with BMI ≥30 kg/m2) as well as sex. It is therefore possible that 
TRAP 5a levels increase in serum of overweight individuals but decrease in the obese state 
which is more severe.  
TRAP 5a is reduced in the serum of obese females but increased in the adipose tissue. In paper 
II and paper III it was shown that TRAP 5a can bind to components of the adipose tissue such 
as nidogen-2 and heparan sulfate. As discussed earlier, proteins with mitogenic effects are often 
binding to ECM proteins to be delivered to the cells or to be stored until they are needed when 
ECM is degraded and they are released. Since TRAP 5a seems to have an effect on 
proliferation, differentiation and migration of pre-adipocytes, thus exhibiting growth factor 
properties, the biological implications of such interactions with components of the ECM could 
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serve the purpose of storage and later release by degradation of the ECM, or as to be delivered 
to the cells for binding on the cell surface.   
Binding of TRAP 5a on the cell surface is accompanied by co-localization with the HPSG 
glypican-4, also suggesting that if the mitogenic effects of TRAP 5a are following a mechanism 
of action similar to growth factors, glypican-4 could act as a co-receptor for TRAP 5a binding. 
Glypican-4 has been shown to enhance the signalling of Wnt 5a and to get endocytosed together 
with Wnt receptor Frizzled-2227, which is consistent with the observation in paper III of co-
localization of TRAP 5a with glypican-4 intracellularly and on cell surface, thus suggesting 
that the endocytosis and effect of TRAP 5a could potentially also be mediated in a similar 
manner as Wnt proteins. This hypothesis could further be strengthened by results from the 
signalling array in paper IV where reduced phosphorylation leading to inhibition of GSK3β 
activity  was observed after TRAP 5a exposure and as discussed previously, GSK3β activity is 
mainly regulated by Akt and Wnt (canonical and non-canonical) signalling. Endocytosis of 
TRAP 5a occurs via the caveolae pathway and even though, generally caveolae pathway is a 
rare route for signalling process but rather for degradation it is responsible for the insulin 
endocytosis and triacylglycerol synthesis in adipocytes 208,209 indicating an importance in 
adipocyte signalling.  Binding of TRAP 5a was also observed for pre-osteoblasts, which is 
similar to what has been shown in previous studies for endocytosis of TRAP and effect on their 
differentiation 151,153,187.   
TRAP 5a was also shown to affect p53, p38 and Bad phosphorylation pattern indicating that 
there might be a potential regulatory role of TRAP 5a in cell cycle arrest/ senescence signalling. 
These data suggest that TRAP 5a could affect both the ‘gas’ and ‘break’ mechanisms of cell 
cycle progression. 
On cellular level TRAP 5a leads apart from increased proliferation to increased migration as 
well as differentiation which in normal tissue could be important for tissue repair. On the other 
hand in pathological situations, dysregulation of TRAP expression could potentially be 
responsible for cell transformation to a more proliferative and migrating phenotype as observed 
for cancer cells with increased TRAP levels.  
 
4.6 REVISED WORKING HYPOTHESIS 
In light of the data in this thesis and previous studies on TRAP 5a action in adipose tissue, a 
revised hypothesis of TRAP 5a action is described in figure 9. A possible mechanism of action 
would be that TRAP 5a is secreted by a subset of macrophages and interacts with components 
of the ECM such as HSPGs and nidogen-2 in order to be stored or delivered to pre-adipocytes 
in close vicinity.  TRAP 5a on the cell surface of pre-adipocytes could bind to a yet unidentified 
receptor either directly or indirectly facilitated by glypican-4 and HSPGs. TRAP 5a 
endocytosis via the caveolae- mediated pathway and presence in multivesicular bodies and 
endosomes could trigger a signalling pathway mediated by changes in phosphorylation of 
GSK3β, leading to various possible outcomes, such as increased cyclin D1 expression and G1 
to S transition and migration and/or differentiation to adipocytes. These outcomes would be 
relevant for tissue homeostasis in a tissue repair/ wound healing situation. If dysregulated, eg 
overexpression, these outcomes could potentially lead to cell transformation. 
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With regard to this hypothesis the following question would be relevant: How can such an 
action from a macrophage- secreted molecule contribute to tissue homeostasis? TRAP 5a 
mutations in humans have been shown to lead to bone dysplasia and autoimmune disorders, 
however there have not been any published observations of complete lack of adipose tissue 
formation 174,177, thus indicating that  TRAP 5a is not critical for embryonic adipose tissue 
development. An alternative explanation could be that TRAP 5a contributes to tissue 
homeostasis in mature adipose tissue in cases where tissue repair or regeneration is needed. As 
previously mentioned, adipose tissue exhibits a stable number of adipocyte cells and an  annual 
turnover of 10% 55,56, however in obesity there is an increased rate of adipocyte cell death and 
increased number of macrophages 98, suggesting an increased need for tissue ‘repair’. Thus, 
one explanation of the biological relevance of TRAP 5a action would be as a part of the tissue 
repair (a wound healing-like action) of adipose tissue in obesity, triggered by macrophages. 
Similar mechanism have been previously shown for macrophages in other types of tissue such 
as skin where M2 anti-inflammatory macrophages express growth factors and stimulate cell 
differentiation and tissue repair in injury sites 96 and TRAP 5a could potentially be a part of the 
tissue repair mechanism in adipose tissue. However, several aspects of this hypothesis need to 
be further investigated.  
 
 
Figure 9. Revised working hypothesis. TRAP 5a secreted from macrophages in adipose tissue binds to the 
ECM probably by interaction with nidogen-2 and heparin or heparan sulfate. TRAP 5a binds to the surface of 
pre-adipocytes in proximity to the HSPG glypican-4 and is endocytosed via the caveolae pathway. 
Intracellularly it is found in early endosomes and multivesicular bodies but is not co-localized with LAMP-1. 
TRAP 5a enhances the proliferation of pre-adipocytes and increases cyclin D1 levels, increases differentiation 
(assessed by lipid droplet acquisition) and causes morphological changes and migration enhancement and 
decrease in FAK, paxillin and actin.  
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4.7 FUTURE PERSPECTIVES AND CLINICAL SIGNIFICANCE  
The revised hypothesis on TRAP 5a action presented above, would indicate several areas of 
research regarding TRAP 5a action.  
Up to today, the subset of macrophages that express TRAP remains unknown and as previously 
described, macrophages can adopt a pro-inflammatory (M1) or anti-inflammatory (M2) 
phenotype as well as intermediate stages. Identification of the phenotype that expresses TRAP 
5a would further contribute to the understanding of the role of TRAP 5a in adipose tissue. 
Additionally stimuli of TRAP expression from macrophages e.g. hypoxia, free fatty acids etc. 
that participate in macrophage recruitment and activation in adipose tissue remain to be 
investigated. Moreover the finding that TRAP 5a serum levels are reduced in the obese state, 
could be further studied by correlating TRAP 5a levels to type of obesity (e.g. hyperplastic or 
hypertrophic), adipocyte size and number. The newly developed TRAP 5a ELISA could be 
used to further investigate the use of this specific isoform as a marker for disease.  
The difference between the functions two isoforms is of particular interest as it represents a 
situation where proteolytical cleavage switches the function from a protein with 
mitogenic/growth factor-like effect (TRAP 5a) to a phosphatase (TRAP 5b). Thus the 
conditions under which this transition occurs would be of interest in future studies.  
Regarding TRAP 5a action in pre-adipocytes, one important future aspect would be the 
identification of the signalling binding partner of TRAP 5a on the pre-adipocyte cell surface. 
Identification of this binding partner would allow for further targeting of TRAP 5a action and 
future use for screening in other tissues for similar action.  
Additionally, the exact signalling pathway of TRAP 5a in pre-adipocytes remains to be 
identified. A future study could involve the testing of hypothesis of wnt signalling- mediated 
TRAP action by the use of wnt signalling receptor inhibitors.  
Finally the hypothesis of TRAP 5a acting as a part of tissue repair mechanism could be further 
tested in other tissues of mesenchymal origin. Studies suggest similar effects in pre-osteoblasts 
thus the effect of TRAP 5a on chondrocytes could also be of interest.  
In summary, further elucidation of TRAP 5a mechanism action by identification of the binding 
partner and signalling pathway could contribute to the development of a drug target for 
hindering increased proliferation, migration and differentiation of pre-adipocytes and thus 
adipose tissue development. Moreover, TRAP 5a mechanism of action could be useful for the 
development of methods to promote adipose tissue regeneration in pathological situations such 
as cachexia where absence of adipose tissue can be life threatening. Additionally, it is of 
importance to investigate if the mechanism applies to other normal tissue types such as bone 
and cartilage or in cancer tissues where TRAP has also been shown to play a role.   
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